Cellular effects of tamoxifen in primary breast cancer
- 1 June 1991
- journal article
- other
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 20 (2), 117-123
- https://doi.org/10.1007/bf01834641
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapyEuropean Journal of Cancer and Clinical Oncology, 1989
- Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer.BMJ, 1988
- Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancerEuropean Journal of Cancer and Clinical Oncology, 1987
- DNA ploidy and survival in breast cancer patientsCytometry, 1987
- A monoclonal antibody, NCRC‐11, raised to human breast carcinoma. 1. Production and immunohistological characterizationHistopathology, 1984
- QUANTITATIVE OESTRADIOL RECEPTOR VALUES IN PRIMARY BREAST CANCER AND RESPONSE OF METASTASES TO ENDOCRINE THERAPYThe Lancet, 1981
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.Journal of Histochemistry & Cytochemistry, 1981
- Recurrent breast cancer treated with the antioestrogen tamoxifen: correlation between hormonal changes and clinical course.BMJ, 1977
- EFFECT OF THE ANTI-OESTROGEN TAMOXIFEN ON PLASMA LEVELS OF LUTEINIZING HORMONE, FOLLICLE-STIMULATING HORMONE, PROLACTIN, OESTRADIOL AND PROGESTERONE IN NORMAL PRE-MENOPAUSAL WOMENJournal of Endocrinology, 1976
- ASSESSMENT OF RESPONSE TO TREATMENT IN ADVANCED BREAST CANCERThe Lancet, 1974